UY29178A1 - Inhibidores de quinasa c-fms - Google Patents
Inhibidores de quinasa c-fmsInfo
- Publication number
- UY29178A1 UY29178A1 UY29178A UY29178A UY29178A1 UY 29178 A1 UY29178 A1 UY 29178A1 UY 29178 A UY29178 A UY 29178A UY 29178 A UY29178 A UY 29178A UY 29178 A1 UY29178 A1 UY 29178A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- diseases
- compounds
- formula
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/70—Nitro radicals
- C07D307/71—Nitro radicals attached in position 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de la fórmula I en ella A, X, R2 y W se definen en memoria descriptiva, así como solvatos, hidratos, tautómeros y sales farmacéuticamente aceptables de los mismos, que inhiben las tirosin quinasas de proteína, especialmente la quinasa c-fms. También se proporcionan métodos para el tratamiento de enfermedades autoinmunes, y enfermedades con un componente inflamatorio; tratamiento de matástasis de cáncer ovárico, de útero, de mama, de colon, de estómago, leucemia de célula pilosa y carcinoma de pulmón de célula no pequena, y tratamiento de dolor, incluyendo dolor esquelético causado por metástasis tumoral u osteoartritis, o dolor visceral, inflamatorio, y neurogénico, así como también osteoporosis, enfermedad de Paget y otras enfermedades en las cuales la resorción ósea media la morbilidad incluyendo artritis, paro de prostesis, sarcoma osteolítico, mieloma, y metástasis tumoral al hueso, con los compuestos de la fórmula I.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62121104P | 2004-10-22 | 2004-10-22 | |
US67017205P | 2005-04-11 | 2005-04-11 | |
US11/254,276 US7662837B2 (en) | 2004-10-22 | 2005-10-20 | Inhibitors of c-fms kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29178A1 true UY29178A1 (es) | 2006-03-31 |
Family
ID=40433511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29178A UY29178A1 (es) | 2004-10-22 | 2005-10-24 | Inhibidores de quinasa c-fms |
Country Status (10)
Country | Link |
---|---|
US (1) | US7662837B2 (es) |
AR (1) | AR051599A1 (es) |
EC (1) | ECSP077409A (es) |
IL (1) | IL182735A (es) |
MY (1) | MY145668A (es) |
NZ (1) | NZ555289A (es) |
PE (1) | PE20060724A1 (es) |
SV (1) | SV2006002669A (es) |
TW (1) | TWI377942B (es) |
UY (1) | UY29178A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
BRPI0710548B8 (pt) * | 2006-04-20 | 2021-05-25 | Janssen Pharmaceutica Nv | inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica |
EP2021329B1 (en) * | 2006-04-20 | 2016-04-13 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
ATE510832T1 (de) | 2006-04-20 | 2011-06-15 | Janssen Pharmaceutica Nv | Heterocyclische verbindungen als c-fms- kinasehemmer |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
AU2013299922B2 (en) | 2012-08-07 | 2018-06-21 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190541A (en) * | 1990-10-17 | 1993-03-02 | Boston Scientific Corporation | Surgical instrument and method |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US5702390A (en) * | 1996-03-12 | 1997-12-30 | Ethicon Endo-Surgery, Inc. | Bioplar cutting and coagulation instrument |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
WO2000042042A2 (en) * | 1999-01-11 | 2000-07-20 | Princeton University | High affinity inhibitors for target validation and uses thereof |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
AU779089B2 (en) * | 1999-04-15 | 2005-01-06 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Cyclic protein tyrosine kinase inhibitors |
US6346625B1 (en) * | 1999-06-23 | 2002-02-12 | Astrazeneca Ab | Protein kinase inhibitors |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
JP4794793B2 (ja) | 1999-12-28 | 2011-10-19 | ファーマコペイア, インコーポレイテッド | N−ヘテロ環TNF−α発現阻害剤 |
US6558385B1 (en) | 2000-09-22 | 2003-05-06 | Tissuelink Medical, Inc. | Fluid-assisted medical device |
US6692491B1 (en) * | 2000-03-24 | 2004-02-17 | Scimed Life Systems, Inc. | Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6613809B2 (en) * | 2001-11-28 | 2003-09-02 | The Regents Of The University Of California | Metal-doped organic gels and method thereof |
BRPI0409136A (pt) * | 2003-04-09 | 2006-04-25 | Japan Tobacco Inc | composto heteroaromático pentacìclico e uso medicinal do mesmo |
JP2007525460A (ja) * | 2003-04-25 | 2007-09-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | c−fmsキナーゼ阻害剤 |
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
-
2005
- 2005-10-20 US US11/254,276 patent/US7662837B2/en not_active Expired - Fee Related
- 2005-10-20 NZ NZ555289A patent/NZ555289A/en not_active IP Right Cessation
- 2005-10-21 TW TW094136915A patent/TWI377942B/zh not_active IP Right Cessation
- 2005-10-21 MY MYPI20054962A patent/MY145668A/en unknown
- 2005-10-21 PE PE2005001242A patent/PE20060724A1/es active IP Right Grant
- 2005-10-24 UY UY29178A patent/UY29178A1/es not_active Application Discontinuation
- 2005-10-24 AR ARP050104445A patent/AR051599A1/es not_active Application Discontinuation
-
2006
- 2006-08-24 SV SV2006002669A patent/SV2006002669A/es unknown
-
2007
- 2007-04-20 EC EC2007007409A patent/ECSP077409A/es unknown
- 2007-04-22 IL IL182735A patent/IL182735A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL182735A0 (en) | 2007-09-20 |
AR051599A1 (es) | 2007-01-24 |
US7662837B2 (en) | 2010-02-16 |
MY145668A (en) | 2012-03-15 |
IL182735A (en) | 2013-10-31 |
TWI377942B (en) | 2012-12-01 |
ECSP077409A (es) | 2007-05-30 |
TW200630092A (en) | 2006-09-01 |
SV2006002669A (es) | 2009-10-15 |
US20060148812A1 (en) | 2006-07-06 |
PE20060724A1 (es) | 2006-09-01 |
NZ555289A (en) | 2010-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31397A1 (es) | Inhibidores de quinasa c-fms | |
UY29178A1 (es) | Inhibidores de quinasa c-fms | |
UA88648C2 (en) | Inhibitors of c-fms kinase | |
ATE437864T1 (de) | Aromatische amide als hemmer der c-fms-kinase | |
UA93085C2 (en) | Inhibitors of c-fms kinase | |
PT2021335E (pt) | Compostos heterocíclicos como inibidores de c-fms quinase | |
FIC20210022I1 (fi) | tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa | |
CY1118112T1 (el) | Διυποκατεστημενες βενζοθειενυλ-πυρρολοτριαζινες και η χρηση τους ως αναστολεις κινασης υποδοχεα του αυξητικου παραγοντα των ινοβλαστων (fgfr) | |
NI200900032A (es) | Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3 | |
CL2008001230A1 (es) | Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. | |
CY1112142T1 (el) | Κυκλοπεντα [d] πυριμιδινες ως αναστολεις της κινασης πρωτεϊνης του ακτ | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
EA201400575A1 (ru) | Способы получения ингибиторов jak киназ и родственных промежуточных соединений | |
EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
ES2667847T3 (es) | Pirimidinas sustituidas útiles como inhibidores de cinasa de EGFR-T790M | |
ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
ECSP034776A (es) | Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos | |
AR026037A1 (es) | Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos | |
UY26988A1 (es) | Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos. | |
TW200745090A (en) | Chemical compounds | |
HK1122795A1 (en) | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase | |
UY27241A1 (es) | Indolinonas sustituidas en posiciones 6, su preparación y utilización como medicamentos | |
UY27968A1 (es) | Derivados de indolinona sustituidos con heterociclos, su preparación y su utilización como medicamentos. | |
TH90382B (th) | อนุพันธ์แอซะอินโดล-2-คาร์บอกซาไมด์ | |
UY26389A1 (es) | Indolinonas sustituidas en posición 6, su preparación y su utilización como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20200624 |